Technology | December 09, 2014

Next generation quality assurance tool delivers expanded breast imaging metrics to provide critical insight for breast imaging workflow

Mammography systems, women's health, RSNA 2014, Volpara, breast density

Image courtesy of Volpara Solutions


December 9, 2014 — Volpara Solutions launched VolparaAnalytics version 1.2 at RSNA 2014. Volpara Solutions showcased the latest version of VolparaAnalytics and the rest of its suite of quantitative breast imaging tools, including VolparaDensity and VolparaDoseRT, which enable personalized measurements of volumetric density, patient-specific dose, breast compression and other factors designed to provide insight for breast imaging quality and workflow.

VolparaAnalytics, a centralized dashboard that presents key mammography metrics, works by automatically collating data from digital mammography and tomosynthesis units to enable cross-comparison of patient populations, mammography systems and operator performance. VolparaAnalytics is in use supporting quality assurance at breast imaging centers around the globe by monitoring critical elements of the breast imaging process and generating key metrics to help breast imaging centers identify and address potential issues early.

The new version of VolparaAnalytics, which will be available in early 2015, features an enhanced user interface and reporting tools, and delivers expanded breast imaging metrics to users including additional quality metrics, new temporal analysis tools, additional tools to analyse patient positioning and patient-dose and time between study acquisitions.

Volpara Solutions was recently recognized with the 2014 Technology Innovation Leadership Award in Breast Imaging from Frost & Sullivan based on independent analysis of the company’s technology excellence and visionary innovation. 

“One key new feature of the latest version of VolparaAnalytics is temporal analysis reporting, which allows users to view key breast imaging metrics such as compression force, applied pressure and mean glandular dose results over time to quickly identify inconsistencies that might have developed,” said Ralph Highnam, PhD., Volpara Solutions CEO and Chief Scientist.  “By providing objective volumetric context, this provides actionable insight to help breast centers improve patient care and productivity.”

VolparaAnalytics runs on top of VolparaDensity, a software tool in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images and to determine which women would benefit from additional screening.  Highly correlated to breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the ACR (American College of Radiology) breast density categories.  To date, more than 4-million women have had their breast density analyzed using VolparaDensity. VolparaDoseRT provides a standardized measurement of patient-specific dose with consistent dose results across mammography systems from different manufacturers.

For more information: www.volparasolutions.com

 


Related Content

News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
Subscribe Now